This Blockbuster Drug Gets a Green Light
Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.
In this week's installment, Bristol-Myers Squibb has gotten the green light from the U.K.'s National Institute of Clinical Excellence for its arthritis drug Orencia. The drug is one of BMY's best performers from last quarter, but there is a lot of big-name competition in this space, and Bristol still has other lingering issues hanging over its head.
One of Orencia's big competitors is Abbott's Humira, and with the impending spinoff of its branded-drug business, Abbott is losing this blockbuster drug. It's a confusing event to understand, with many investors left wondering what to do with these two stocks once they're separated. To help investors better understand the upcoming event, the Fool has created a brand new premium report outlining both Abbott Labs and its spinoff, AbbVie. Inside, we outline all of the must-know opportunities and risks facing both companies, so make sure to claim this 2-for-1 report by clicking here now.
The article This Blockbuster Drug Gets a Green Light originally appeared on Fool.com.Brenton Flynn and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.